Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million
15.10.2019 23:12:00 EEST | Business Wire | Press release
Dubai World Congress for Self-Driving Transport; organised by Roads and Transport Authority (RTA) Dubai on 15th and 16th October 2019 has attracted more than 700 technology leaders and innovators as well as 3000 visitors of the accompanying exhibition. The congress focuses on cutting-edge technologies, besides discussing and developing a general legislative structure for autonomous transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015006107/en/
Winners of the Dubai World Self-Driving Transport Challenge (Photo: AETOSWire)
The event is part of RTA’s efforts in support of the strategy unleashed by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, to make 25% of all trips in Dubai smart and driverless by 2030. The congress attracted 80 international experts, including five keynote speakers, who will be taking part in 40 lectures and 39 technical workshops.
The congress is shaping into an all-inclusive global platform for self-driving transport that brings together top experts, policymakers, technology developers, researchers and academia. The event aims to highlight the leading role of Dubai Government in self-driving transport and accelerate the drive to achieve the targets of Dubai Autonomous Transportation Strategy through attracting experts and technologies of self-driving transport to Dubai. The event also aims to raise public awareness about the latest technologies and future trends of transportation as well as identifying the potential impacts on investments and different transport strategies.
Dubai Challenge
Dubai World Challenge for Self-Driving Transport, which carries prize money of US$5.1 million (about 19m Dirhams) attracted 65 entities from 20 countries, 15 of them qualified for the finals. The challenge focused on the first and last-mile challenge of mobility journeys.
Five leading companies, three start-ups and seven local and foreign universities qualified for the finals. Qualifying vehicles were subjected to different scenarios and tests on a dedicated track tailor-made for testing such vehicles at the Dubai Silicon Oasis.
Tests carried included stopping at bus stops, forced stop, overtaking a stopping vehicle, overtaking a bike, and dealing with various traffic scenarios such as signals, pedestrian crossing, road works, and sand on road. Tests also covered negotiating a roundabout, handling of humps, rains and high-speed turns.
Nominees for the challenge were qualified on certain parameters including the status, credibility, vision, skills and relevant experience of the entity. They were then subjected to several tests in various categories to assess their performance under six key standards and 18 subsidiary standards. Key standards covered the operation plan, tolerance and reliability, sustainability and energy, customer experience, safety and security, and dealing with road users.
Awards
The list of winners was delivered by autonomous delivery bot Roxo developed by FedEx Express in a fitting move with Dubai being selected as the first city outside the USA to host the test of this personal delivery bot. French companies swept the prizes of leading companies amounting to USD 3 million. Gaussin won the sustainability and energy award, Navya won the durability and reliability award as well as the customers' experience award.
In the start-ups category the first USD 1 million went to Sensible 4 from Finland, while the runner-up was iAuto from Taiwan who bagged USD 500,000 while UAE-based Derq Company finished third.
Amongst the international universities, the winner was Freie Universität Berlin which received USD 200,000; while Carlos III de Madrid University won second place with USD 100,000 and the Australian University UTS came third. In the local universities, Dubai University finished first with USD 200,000; UAE University came second bagging USD 100,000 and Al Ain University was third.
The Dubai World Challenge for Self-Driving Transport comprised several phases. In February 2018 the challenge was announced, and in October 2018 qualifiers for Phase II were announced. In February 2019, Phase II started and in March tests started at Dubai Silicon Oasis. From April to June this year, a team made overseas visits to Taiwan, Finland, Australia, Germany and Spain to assess start-ups and academia. In July qualifiers arrived in Dubai to collect geographical data about test tracks and draw maps, and in August vehicle tests started on the challenge track. Winners were selected according to results achieved in tests.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015006107/en/
Contact information
Roads and Transport Authority (RTA)
Maryam Al Balooshi, Manager, Media Communication
Marketing and Corporate Communication Department
Tel: +97142902699
Email Maryam.HAlblooshi@rta.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
